Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor

Nature Structural Biology

Volumn 9, Issue 10, 2002, Pages 745-749

  Davies, Thomas G ^a   Bentley, Johanne ^b   Arris, Christine E ^b   Boyle, F Thomas ^c   Curtin, Nicola J ^b   Endicott, Jane A ^a   Gibson, Ashleigh E ^b   Golding, Bernard T ^b   Griffin, Roger J ^b   Hardcastle, Ian R ^b   Jewsbury, Philip ^c   Johnson, Louise N ^a   Mesguiche, Veronique ^b   Newell, David R ^b   Noble, Martin E M ^a   Tucker, Julie A ^a   Wang, Lan ^b   Whitfield, Hayley J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Safety Assessment Alderley Park   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 O CYCLOHEXYLMETHYL 2 (4' SULFAMOYLANILINO)PURINE; 6 O CYCLOHEXYLMETHYLGUANINE DERIVATIVE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; GUANINE DERIVATIVE; METHYLGUANIDINE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR CELL LINE;

CDC2 PROTEIN KINASE; CDC2-CDC28 KINASES; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; ENZYME INHIBITORS; GUANINE; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0036785882     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb842     Document Type: Article

References (23)

1. Sielecki, T.M., Boylan, J.F., Benfield, P.A. & Trainor, G.L. J. Med. Chem. 43, 1-18 (2000).
2. Senderowicz, A.M. & Sausville, E.A. J. Natl. Cancer Inst. 92, 376-387 (2000).
3. Meijer, L., Leclerc, S. & Leost, M. Pharmacol. Ther. 82, 279-284 (1999).
4. Arris, C.E. et al. J. Med. Chem. 43, 2797-2804 (2000).
5. Schulze-Gahmen, U. et al. Proteins 22, 378-391 (1995).
6. De Azevedo, W.F. Jr, LeClerc, S., Meijer, L., Havlicek, L., Strnad, M. & Kim, S.-H. Eur. J. Biochem. 243, 518-526 (1997).
7. Gray, N.S. et al. Science 281, 533-538 (1998).
8. Hoessel, R. et al. Nature CellBiol. 1,60-67 (1999).
9. Russo, A.A., Jeffrey, P.D. & Pavletich, N.P. Nature Struct. Biol. 3, 696-700 (1996).
10. Gibson, A.E. et al. J. Med. Chem. 45, 3381-3393 (2002).
11. Davies, T.G., Pratt, D.J., Endicott, J.A., Johnson, L.N. & Noble, M.E.M. Pharmacol. Ther. 95, 125-133 (2002).
12. Davies, T.G. et al. Structure 9, 389-397 (2001).
13. Juffer, A.H., Eisenhaber, E, Hubbard, S.J., Walther, D. & Argos, P. Protein Sc. 4, 2499-2509 (1995).
14. Fletcher, D.A., McMeeking, R.F. & Parkin, D. J. Chem. Inf. Comput. Sci. 36, 746-749 (1996).
15. Zarkowska, T. & Mittnacht, S. J. Biol. Chem. 272, 12738-12746 (1997).
16. Peter, M., Nakagawa, J., Doree, M., Labbe, J.C. & Nigg, E.A. Cell 60, 791-801 (1990).
17. Brown, N.R., Noble, M.E.M., Endicott, J.A. & Johnson, L.N. Nature Cell Biol. 1, 438-443 (1999).
18. Leslie, A.G.W. Joint CCP4 and ESF-EAMCB Newsletter on Protein Crystallography 26 (Science and Engineering Research Council UK, Daresbury Laboratory, Warrington; 1992).
19. Evans, P.R. in Proceedings of CCP4 Study Weekend (eds Sawyer, L., Isaacs, N. & Bailey, S.) 114-122 (Science and Engineering Research Council UK, Daresbury Laboratory, Warrington; 1993).
20. Murshudov, G.N., Vagen, A.A. & Dodson, E.J. Acta Crystallogr. D 53, 240-255 (1997).
21. Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard. M. Acta Crystallogr. A 47, 110-119 (1991).
22. Lamzin, V.S. & Wilson, K.S. Acta Crystallogr. D 49, 129-147 (1993).
23. Davies, S.P., Reddy, H., Caivano, M. & Cohen, R Biochem J. 351, 95-105 (2000).